Skip to main content

Alexion Mission

At Alexion, our mission is to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, as well as supportive technologies and healthcare services.

For over three decades, patients and their caregivers have been at the centre of everything we do. Everyday, we are inspired to think differently and follow the science in order to create better outcomes for them and their families. Our mission is driven by understanding who they are as unique individuals, not just their disease.

Sustainability

We are committed to sustainability in Ireland, for the local communities, and for our colleagues. We recognise the connection between a healthy planet and healthy people and are committed to proactively managing our environmental impact.

Across our sites we have invested in infrastructure projects utilising new technologies that help reduce water usage, and bring in sustainable heat and energy sources. We have also converted our road freight in Ireland and out across the EU to green fuels reducing our road freight carbon emissions by 90%. Additionally we work with local environment groups to support ecology projects across Ireland, recently launching a project to reintroduce Atlantic rain forests to the West Coast of Ireland. These investments will continue as we work towards our goal of being net zero by 2045.

Rare Diseases Supported in Ireland

Patients across Ireland are served by Alexion's United Kingdom and Ireland affiliate. Which works to provide innovative treatments to patients with life-threatening rare diseases and devastating conditions for which there are few, if any, effective treatment options. Globally, Alexion works across multiple diseases and devastating conditions, including this listed below.

Paroxysmal Nocturnal Haemoglobinuria (PNH)

 

Atypical Haemolytic Uraemic Syndrome (aHUS)

 

Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN)

 

Generalised Myasthenia Gravis (gMG)

 

Neuromyelitis Optica Spectrum Disorder (NMOSD)

 

Hypophosphatasia (HPP)

 

Lysosomal Acid Lipase Deficiency (LAL-D)

 

Clinical Trials

Clinical Trials

Alexion is committed to serving people affected by rare diseases through the discovery, development and access of life-changing medicines. Our goal is to bring safe and effective medicines to as many patients as possible by conducting rigorous clinical trials and obtaining marketing approval by regulatory authorities around the world. Our work is marked by a commitment to the highest standards of preclinical and clinical research, and an acute sense of urgency. As such, we prioritise access to our investigational medicines through participation in a clinical trial.

Transparency and Disclosure

Alexion is committed to operating with integrity, accountability, and transparency, and to complying with all applicable laws and regulations.

As Alexion Irelands commercial and marketing Alexion fully participates in the Association of British Pharmaceutical Industry’s (ABPI) Disclosure UK initiative to increase transparency about the relationships we have with doctors, nurses, pharmacists, and other healthcare professionals across the UK and Ireland.

Careers

Career Opportunities

At Alexion, we foster an environment that attracts and retains the best talent. We provide the tools to enable each individual to perform at their personal best so that we maximise our collective impact.

Alexion Pharma International Operations Limited

Veeva ID: M/IE/UNB-U/0013

Date of Preparation: February, 2025